首页> 美国卫生研究院文献>SpringerPlus >Virtual screening for oseltamivir-resistant a (H5N1) influenza neuraminidase from traditional Chinese medicine database: a combined molecular docking with molecular dynamics approach
【2h】

Virtual screening for oseltamivir-resistant a (H5N1) influenza neuraminidase from traditional Chinese medicine database: a combined molecular docking with molecular dynamics approach

机译:从中药数据库中虚拟筛选对奥司他韦耐药的(H5N1)流感神经氨酸酶的分子对接与分子动力学方法的组合

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The neuraminidase (NA) of the influenza virus is the target of antiviral drug, oseltamivir. Recently, cases are reported that Influenza virus becoming resistant to oseltamivir, necessitating the development of new long-acting antiviral compounds. Most importantly, H274Y mutation in neuraminidase exhibits high levels of resistance to oseltamivir. In this report, a novel class of lead molecule with potential NA inhibitory activity was found from the traditional Chinese medicine database (TCMD) using virtual screening approach. Initially ADME properties of the lead compounds were analyzed with respect to the Lipinski rule of five. Subsequently, the data reduction was carried out by employing molecular docking study. Final validation was done by means of molecular dynamic simulations. The toxicity profiles for the screened compound were also analyzed. The result indicates that neoglucobrassicin (a compound derived from TCMD) become a promising lead compound and be effective in treating oseltamivir-resistant influenza virus strains.
机译:流感病毒的神经氨酸酶(NA)是抗病毒药物奥司他韦的靶标。最近,有报道称流感病毒对奥司他韦具有耐药性,因此有必要开发新的长效抗病毒化合物。最重要的是,神经氨酸酶中​​的H274Y突变表现出对奥司他韦的高水平抗药性。在本报告中,使用虚拟筛选方法从中药数据库(TCMD)中发现了一类具有潜在NA抑制活性的新型铅分子。最初,相对于5的Lipinski规则分析了先导化合物的ADME性质。随后,通过分子对接研究进行数据约简。最终验证是通过分子动力学模拟完成的。还分析了所筛选化合物的毒性概况。结果表明,新葡糖嘧啶(源自TCMD的化合物)成为有前途的先导化合物,并有效治疗耐奥司他韦的流感病毒株。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号